IOBT IO Biotech Inc
382
$1.58
$0.08
(5.33%)
| Watchers | 382 |
| 52-Wk Low | $0.8163 |
| 52-Wk High | $2.28 |
| Market Cap | $104.09M |
| Volume | 34,031.00 |
| 52-Wk High | $2.28 |
| 52-Wk Low | $0.8163 |
IO Biotech appoints Faical Miyara as CBOThe Fly • about 1 month ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,600 shares, a...
Evotec (OTCMKTS:EVTCY Get Free Report) and IO Biotech (NASDAQ:IOBT Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based...
Acciones al alza
SCWorx (NASDAQ:WORX) crecieron un 49,12% para establecerse en los 2,55 d lares durante la sesi n del after-market del mi rcoles.
IO Biotech (NASDAQ:IOBT) experimentaron un repunte...
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a...
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA (pembrolizumab), in patients with advanced melanoma...
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...
IO Biotech, Inc. (NASDAQ:IOBT Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling...
IO Biotech: A Phase 3 Company Getting No Respect...